SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
Phase 1
Completed
- Conditions
- Extracranial Solid NeoplasmAdvanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
- Interventions
- Biological: Anti-OX40 Antibody BMS 986178Drug: TLR9 Agonist SD-101
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 12
- Registration Number
- NCT03831295
- Locations
- 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 1
Completed
- Conditions
- B-Cell Non-Hodgkin LymphomaSmall Lymphocytic LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaLymphoplasmacytic LymphomaMantle Cell LymphomaMarginal Zone Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisRadiation: Radiation TherapyDrug: TLR9 Agonist SD-101
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 14
- Registration Number
- NCT03410901
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Phase 2
Completed
- Conditions
- Lymphomas: Non-HodgkinLymphoma, Non-HodgkinLymphomaLymphomas: Non-Hodgkin Follicular / Indolent B-Cell
- Interventions
- Radiation: Local radiotherapy
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 30
- Registration Number
- NCT00880581
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Phase 2
Completed
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Biological: CpG-MCL vaccineBiological: PF-3512676Procedure: Vaccine-primed T-cellsProcedure: Autologous hematopoietic stem cell transplant (HSCT)Drug: Standard induction chemotherapy
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 59
- Registration Number
- NCT00490529
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Phase 1
Completed
- Conditions
- Non-Hodgkin LymphomaMycosis Fungoides
- Interventions
- Drug: CPG 7909
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Ronald Levy
- Target Recruit Count
- 30
- Registration Number
- NCT00185965
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
© Copyright 2025. All Rights Reserved by MedPath